The Enterprise Value as of January 2026 (TTM) for Coherus Oncology, Inc. (CHRS) is 218.97M

According to Coherus Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 218.97M. This represents a change of 41.00% compared to the average of 155.30M of the last 4 quarters.

Coherus Oncology, Inc. (CHRS) Historical Enterprise Value (quarterly & annually)

How has CHRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Coherus Oncology, Inc. over the last ten years is 852.43M. The current 218.97M Enterprise Value has changed 2.47% with respect to the historical average. Over the past ten years (40 quarters), CHRS's Enterprise Value was at its highest in in the June 2019 quarter at 1.64B. The Enterprise Value was at its lowest in in the June 2025 quarter at -90976370.68.

Coherus Oncology, Inc. (CHRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Coherus Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Coherus Oncology, Inc. (CHRS) Average Enterprise Value

How has CHRS Enterprise Value performed in the past?

The current Enterprise Value of Coherus Oncology, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Coherus Oncology, Inc. (CHRS) Enterprise Value vs. Peers

How is CHRS’s Enterprise Value compared to its peers?

Coherus Oncology, Inc.’s Enterprise Value is greater than OmniAb, Inc. (192.71M), greater than Invivyd, Inc. (163.26M), less than SELLAS Life Sciences Group, Inc. (366.20M), greater than Codexis, Inc. (160.21M), greater than Avalo Therapeutics, Inc. (145.27M), greater than Protalix BioTherapeutics, Inc. (161.00M), greater than C4 Therapeutics, Inc. (142.16M), greater than Insight Molecular Diagnostics Inc. (174.19M), greater than Sangamo Therapeutics, Inc. (167.52M), less than Protara Therapeutics, Inc. (261.23M),

Build a custom stock screener for Coherus Oncology, Inc. (CHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Coherus Oncology, Inc. (CHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Coherus Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.